FDA created a compounding pharmacy advisory committee in mid-December. The committee consists of 12 voting and two non-voting members and is designed to give advice and recommendations relating to regulatory changes for compounding manufacturers and the implementation of the compounding provisions in Title 1 of the Drug Quality and Security Act (DQSA) (see IPQ December 28, 2013. IPQ will be providing an in-depth update on implanting the compounding provisions of DQSA in January.)
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
